Lifestyle Modification and Incretin-Based Therapy for Obesity. Weight loss achieved with minimal advice on lifestyle but remains critical for long term success. https://t.co/gZwidnzrrP
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial - https://t.co/K0fkI6Nycl
Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial https://t.co/DDgTHL6T2q
NICE continues to make Evidence Based recommendations now it is down to ICB and clinicians to make sure that these benefits reach all patients @DrDerekConnolly
New recommendation: Semaglutide (Wegovy) can now be prescribed to help protect the heart, not just to manage weight: https://t.co/BH4w1kI4So
It's for adults who've already had a heart attack, stroke, or cardiovascular event and have a BMI of 27 or above.
No increase risk of NAION with GLP-1. Pooled data from around 97,000 patients-from randomised placebo-controlled trials with semaglutide and liraglutide do not show an increased incidence of NAION in participants receiving GLP-1RA treatment. https://t.co/y3DYsMgfPo
Very disheartening that an excellent medication that helps to save and change lives for millions in India with diabetes and obesity is being made spuriously. Risking lives. Authorities please act @PMOIndia@DrJitendraSingh@JPNadda
Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease | Link between Gut Liver axis in the pathogenesis on MASLD https://t.co/51S9Zdinkt
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - https://t.co/W8jKOAEGvz
Our paper led by @samiul_m Effect of Behavioral Sleep Interventions on Measures of Obesity, Dietary Intake and Physical Activity in Adults With Poor Sleep Health: A Systematic Review, Meta‐Analysis and Meta‐Regression Analysis - https://t.co/9Ffn308wkc